Dr. Torge Rempe, MD

Dr. Rempe practices at UF Health Shands Hospital in Gainesville, Florida, part of UF Health.

Dr. Rempe's NPI, 1639521545, was assigned on July 5, 2016. Dr. Rempe graduated from Univ Kiel- Christian- Albrechts- Fac Med in 2012. Dr. Rempe holds Florida license ME149662.

Dr. Rempe's primary practice is UF Health Shands Hospital, at 1600 SW Archer Rd, Gainesville, FL 32610 in Alachua County. The practice phone is (352) 265-8000.

Dr. Rempe's primary practice is UF Health Shands Hospital in Gainesville, Florida, part of UF Health. The medical group on file is UF Health Physicians. Dmand AI also links Dr. Rempe to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rempe practices. Vendor and product names are available with a free account.

Neurology is Dr. Rempe's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Rempe is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Rempe's licenses on file in 2 states: Florida and California.

Dmand AI lists epilepsy, fibromyalgia and chronic pain, headaches, multiple sclerosis, neuropathy and seizures among the conditions Dr. Rempe treats.

CMS data shows 272 Medicare services from Dr. Rempe across 6 procedure codes in 2024, for 133 Medicare patients. Medicare paid $23,488 for them.

CMS counts 133 Medicare patients who saw Dr. Rempe in 2024. The largest group is 65 to 74, with 51 patients. 71% of them have high blood pressure, and 69% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rempe's median patient age at 65, with 68% women.

In 2024, Dr. Rempe wrote 540 Medicare Part D claims for 91 patients. 81% of them were for generic drugs. CMS names the drug for 366 of them, across 15 drugs with 11 or more claims each, at $613,814 in total drug cost. In 2023, CMS named 398 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Dr. Rempe for performance year 2024, reported through an alternative payment model (APM). Dr. Rempe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rempe as offering telehealth.

Dmand AI links 25 papers to Dr. Rempe, published from 2014 to 2025. 2020 was the busiest year, with 5. The most frequent topics are Magnetic Resonance Imaging, Autoantibodies and Immunologic Factors. Dr. Rempe has published most often in Mult Scler Relat Disord. Dr. Rempe's most frequent co-authors are Jennifer S. Graves, MD, Elsa Cassandra Rodriguez, MD and John Herbert Rees, MD.

Dmand AI links Dr. Rempe to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis.

CMS Open Payments shows 51 general payments to Dr. Rempe from 8 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 80% of the total. Alexion Pharmaceuticals, Inc. paid the most, $12,453. It also lists 2 research payments totaling $95 in 2025.

Dmand AI lists 5 awards for Dr. Rempe, most recently Kenneth M. Heilman Award for Excellence in Research in 2020.

Dr. Rempe graduated from Univ Kiel- Christian- Albrechts- Fac Med in 2012.

Dr. Rempe is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.